Close Menu

Breaking News

Agilent has agreed to provide customized high-fidelity oligo microarrays for the nucleic acid detection step in SomaLogic's Somascan assay.

Using genome sequence data for 429 accessions, an international team tracked chickpea's origin and spread, while identifying markers for important traits.

The in vitro diagnostic is designed to detect whole gene segments for influenza A and B viruses and can characterize viruses as seasonal or nonseasonal.

The firm will acquire GenePOC for $50 million with potential for milestone payments of an addition $70 million by Meridian's fiscal 2023.

The firm's clinical service revenues were up also 51 percent, and it also announced it has signed a contract with insurer Humana.

The new funding brings the Series B total to £23.3 million for the British clinical decision support technology developer.

Whole-genome sequencing on 62 families revealed rare reproduction- and metabolism-related variants in the androgen production pathway gene DENND1A.

The firm reported double-digit organic growth in North America, Europe, and China, driven in part by sales from its antibody portfolio and Simple Western instruments.

Caprion said that the acquisition helps it acquire expertise in the analysis of myeloid-derived suppressor cells and expand its geographic coverage.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

The 'forest tundra,' 'steppe-forest,' and 'southern steppe' populations all have slightly different genetic ancestry contributions.

Canopy aims to use Zellkraftwerk's microfluidic cell-capture technology to further develop drug-development research and biomarker discovery.

The companies were involved in a dispute over NeoGenomics' handling of Health Discovery technology it licensed in 2012 to develop cancer tests.

The project plans to sequence 20,000 genomes in 2019, 50,000 by the end of 2020, and a total of 100,000 by the end of 2021 using Oxford Nanopore's PromethIon platform.

Last week, GenomeWeb's readers were most interested in the ninth round of Illumina's accelerator program.

Interpace Diagnostics announced this week that it has received accreditation from the College of American Pathologists for its Pittsburgh, Pennsylvania and New Haven, Connecticut laboratories.

Gencove offers low-coverage whole-genome sequencing and has developed imputation algorithms and informatics to extract useful information from the data.

The cancer diagnostics developer said it was undertaking the reverse stock split in order to meet the Nasdaq's $1 minimum bid price requirement.

A bi-weekly listing of recent local coverage determinations from Medicare Administrative Contractors.

While total revenues were up less than 1 percent, the Diagnostics division grew revenues 5 percent. Discovery & Analytical Solutions dipped 2 percent.

The company also said that effective Thursday, consumer genomics firm Helix would be deconsolidated with former Illumina executive Marc Stapley joining as Helix CEO.

The acquisition of OTTR Complete Transplant Management will enable CareDx to integrate the EMRs of patients at transplant centers with longitudinal patient surveillance data.

The acquisition will allow the firms to provide annotated biospecimens, as well as sequencing, bioinformatics, and lab services to hospitals and clinicians.

Pages

Retraction Watch reports that a paper was pulled because it refers to a gene that doesn't exist in mice.

Researchers were able to generate fertilized northern white rhinoceros eggs, according to Mashable.

Former Orig3n employees raise concerns about its testing at Bloomberg Businessweek.

In PLOS this week: microRNA expression changes in hepatocellular carcinoma, real-time PCR-based approach for diagnosing schistosomiasis, and more.